Tinnitus - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Tinnitus - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Tinnitus - Pipeline Review, H2 2014', provides an overview of the Tinnitus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tinnitus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tinnitus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Tinnitus
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Tinnitus and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Tinnitus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Tinnitus pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Tinnitus
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Tinnitus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Tinnitus Overview 7
Therapeutics Development 8
Pipeline Products for Tinnitus - Overview 8
Pipeline Products for Tinnitus - Comparative Analysis 9
Tinnitus - Therapeutics under Development by Companies 10
Tinnitus - Therapeutics under Investigation by Universities/Institutes 11
Tinnitus - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Tinnitus - Products under Development by Companies 16
Tinnitus - Products under Investigation by Universities/Institutes 17
Tinnitus - Companies Involved in Therapeutics Development 18
Merz Pharma GmbH & Co. KgaA 18
Auris Medical Holding AG 19
Knopp Biosciences LLC 20
Otonomy, Inc. 21
Sound Pharmaceuticals, Inc. 22
Synphora AB 23
Flexion Therapeutics, Inc. 24
Autifony Therapeutics Limited 25
AudioCure Pharma GmbH 26
Tinnitus - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 35
neramexane mesylate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
esketamine hydrochloride - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
latanoprost - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SPI-1005 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SPI-3005 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AUT-00063 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
gacyclidine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AUT-3 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
acamprosate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
AM-102 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drug to Activate KCNQ for Tinnitus - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules for Tinnitus - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Drug For Tinnitus - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Tinnitus - Recent Pipeline Updates 53
Tinnitus - Dormant Projects 57
Tinnitus - Product Development Milestones 58
Featured News & Press Releases 58
Jun 04, 2014: Autifony Therapeutics awarded �2.2 million to progress first-in-class drug for tinnitus into Phase IIa study 58
Mar 31, 2014: Published Analysis Confirms Positive Results from Auris Medical's Phase IIb Study with AM-101 in Treatment of Acute Inner Ear Tinnitus 58
Sep 09, 2013: Second Phase II Clinical Trial Confirms Safety and Efficacy Trends for Auris Medical AG's AM-101 in Treatment of Acute Peripheral Tinnitus 60
Jun 04, 2013: Autifony Therapeutics Initiates Phase I Trial Of AUT-00063 For Treatment Of Hearing Loss And Tinnitus 61
May 17, 2013: Auris Medical Announces Presentation Of Safety Results From AM-101 Clinical Development At 7th International TRI Tinnitus Conference 61
Apr 30, 2013: Auris Medical Selects Medidata Clinical Cloud To Support New Tinnitus Research 62
Feb 12, 2013: Auris Medical Completes Enrollment In Phase II Study Of AM-101 For Treatment Of Acute Peripheral Tinnitus 63
Aug 10, 2012: Auris Medical Completes Enrolment In First Stage Of AM-101 TACTT1 Study 63
Jun 26, 2012: Auris Medical Presents Key Results From Phase IIb Study Of AM-101 At International TRI Tinnitus Conference 63
Oct 17, 2011: Auris Medical Reports Positive Results From Phase IIb Trial With AM-101 For Treatment Of Acute Inner Ear Tinnitus 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Number of Products under Development for Tinnitus, H2 2014 8
Number of Products under Development for Tinnitus - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Comparative Analysis by Unknown Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Tinnitus - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2014 18
Tinnitus - Pipeline by Auris Medical Holding AG, H2 2014 19
Tinnitus - Pipeline by Knopp Biosciences LLC, H2 2014 20
Tinnitus - Pipeline by Otonomy, Inc., H2 2014 21
Tinnitus - Pipeline by Sound Pharmaceuticals, Inc., H2 2014 22
Tinnitus - Pipeline by Synphora AB., H2 2014 23
Tinnitus - Pipeline by Flexion Therapeutics, Inc., H2 2014 24
Tinnitus - Pipeline by Autifony Therapeutics Limited, H2 2014 25
Tinnitus - Pipeline by AudioCure Pharma GmbH, H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Number of Products by Stage and Target, H2 2014 29
Number of Products by Stage and Mechanism of Action, H2 2014 31
Number of Products by Stage and Route of Administration, H2 2014 33
Number of Products by Stage and Molecule Type, H2 2014 34
Tinnitus Therapeutics - Recent Pipeline Updates, H2 2014 53
Tinnitus - Dormant Projects, H2 2014 57